Table 2: Pseudomonas aeruginosa isolates 2019 stratified by infection type and percentage of isolates with resistant phenotypes.
|
Infection type/Resistant |
MDR |
XDR |
PDR |
Ceftazidime |
Meropenem |
|
Pneumonia (n = 110) |
11.8% |
21.8% |
0.0% |
29.6% |
35.5% |
|
Skin-soft tissue (n = 44) |
2.3% |
13.6% |
0.0% |
20.8% |
16.0% |
|
Intra-abdomen (n = 42) |
2.4% |
7.1% |
0.0% |
18.8% |
16.1% |
|
Urinary tract (n = 18) |
5.6% |
61.1% |
0.0% |
76.0% |
72.0% |
|
Bloodstream (n = 10) |
0.0% |
20.0% |
0.0% |
22.2% |
22.2% |
|
Total (n = 224) |
7.1% |
20.5% |
0.0% |
30.8% |
32.0% |
MDR: Multidrug Resistant; EDR: Extensively Drug Resistant; PDR: Pan Drug Resistant; NS: Non-Sensible. Criteria as published by European Committee on Antimicrobial Susceptibility Testing (EUCAST) 2018.